Genmab | GEN - PE Price to Earnings


Genmab reported 16.04 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
Agios Pharmaceuticals 3.56 0 Mar/2026
Almirall 79.43 0.3 Dec/2025
Amarin 91.05 88.3 Jun/2023
Amgen 18.6 0.53 Sep/2026
argenx SE 33.43 2.1 Sep/2026
AstraZeneca 24.63 0.71 Sep/2026
Bayer 4.61 0.47 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Demant 20.6 6.87 Jun/2026
Exelixis 18.43 0.41 Sep/2026
Fresenius Medical Care 8.23 3.9 Sep/2026
Genmab 16.04 1.05 Jun/2026
GlaxoSmithKline 9.72 0.9 Sep/2026
GN Store Nord 9.38 1.39 Jun/2026
GRIFOLS 13.04 1.66 Sep/2026
Hikma Pharmaceutical 10.43 3.72 Dec/2025
Lakefront Biotherapeutics 2.68 0.14 Jun/2026
Lonza 34.34 2.58 Dec/2025
Merck 17.21 4.47 Jun/2026
Novartis 19.17 3.24 Sep/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 22.34 3.38 Sep/2026
UCB 29.7 5.52 Dec/2025